|
Lebon [30]
|
2010
|
case study
|
25
|
25-100
|
levomepromazine in combination with midazolam
|
|
Alonso-Babarro [31]
|
2010
|
retrospective cohort study
|
125
|
100-150
|
indications: pain, delirium
|
|
D'Cruz [32]
|
2009
|
case report
|
no data
|
no data
|
indication: agitation/delirium
|
|
Stephenson [33]
|
2008
|
retrospective chart review
|
9.4
|
2.5–75
|
2006
|
1996 levomepromazine was often used first line, 2006 midazolam was used first line and levomepromazine as an adjunct
|
|
75
|
25–150
|
1996
|
|
Reuzel [34]
|
2008
|
survey study
|
no data
|
no data
|
most common indications: pain and dyspnoea
|
|
Sykes [46]
|
2003
|
retrospective case–control study
|
125
|
125-200
|
indication: continuing agitation
|
|
Gambles [36]
|
2001
|
descriptive retrospective study
|
no data
|
6.25-12.5
|
indication: agitation/restlessness
|
|
Morita E [37]
|
2001
|
prospective study
|
50
|
50
| |
|
Fainsinger [38]
|
2000
|
prospective observational multicenter study
|
no data
|
no data
|
most common indication: delirium
|
|
Chater [39]
|
1998
|
survey study
|
100
|
50–250
| |
|
Stone [40]
|
1997
|
retrospective chart review
|
64
|
no data
|
levomepromazine was usually prescribed in combination with another sedative
|
|
Oliver ) [41]
|
1985
|
retrospective chart review
|
no data
|
37.5-300
|
indications: confusion/agitation, pain, vomiting (not palliative sedation as main indication)
|
|
Mercadante [42]
|
2011
|
SR
|
no data
|
100-150
|
based on [39]
|
|
DeGraeff [43]
|
2007
|
SR
|
64
|
25-250
|
based on [39][40, 45, 46]
|
|
Morita T [25]
|
2005
|
SR
|
no data
|
5-12,5
|
guideline is based on a Delphi process conducted by the Sedation Guideline Task Force
|
|
Cowan [45]
|
2001
|
SR
|
64
|
48-600
|
based on [40, 41]
|
